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Objective. IDH1 codon 132 mutation (mostly Arg132His) is frequently found in gliomas and is associated with longer survival.
However, it is still unclear whether IDH1mutation renders the cell more vulnerable to current treatment, radio- and chemotherapy.
Materials and Methods. We transduced U87 with wild type IDH1 or 𝐼𝐷𝐻1𝑅132𝐻 expressing lentivirus and analyzed the
radiosensitivity (dose ranging 0 to 10 Gy) under normoxia (20% O
2
) and moderate hypoxia (1% O
2
). Results. We observed that
𝐼𝐷𝐻1
𝑅132𝐻U87 cells grow faster in hypoxia andweremore sensitive to radiotherapy (in terms of cellmortality and colony formation
assay) compared to nontransduced U87 and IDH1𝑤𝑡 cells.This effect was not observed in normoxia. Conclusion. These data suggest
that 𝐼𝐷𝐻1𝑅132𝐻 mutation increases radiosensitivity in mild hypoxic conditions.
1. Introduction
The IDH1 gene encoding the cytoplasmicNADP+-dependent
isocitrate dehydrogenase—and more rarely IDH2, encod-
ing the mitochondrial isoform—are frequently mutated in
gliomas, especially low grade gliomas and secondary glioblas-
tomas [1]. IDH1/IDH2 mutation is associated with better
clinical outcome, whatever the grade, but it is still not clear
whether it is merely a prognostic marker or a predictor
of the response to radiotherapy or chemotherapy [2–6].
Recent data IDH1/IDH2 mutation results in a new enzyme
function catalyzing the NADPH-dependent reduction of
alpha-ketoglutarate to D-2-hydroxyglutarate (D-2HG) [7].
IDH1/IDH2 mutations result in D-2HG accumulation and
lowering NADPH levels. On one hand D-2HG inhibits
various alpha-ketoglutarate dependant reactions, including
histone and DNA demethylation, and is likely to promote—
rather than inhibit—HIF1𝛼 degradation [8–11]. On the other
hand, low NADPH levels might sensitize tumors to oxida-
tive stress, potentiating response to radiotherapy, and may
account for the prolonged survival of patients harboring the
mutations.
Since the majority of gliomas are poorly responsive
to current treatment regimens, the ability to enhance cell
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Figure 1: Real time PCR quantified the expression of the IDH1wt and IDH1R132H transduced genes.













Days after seeding Days after seeding






















Figure 2: Effect of IDH1R132H on U87 cell proliferation. U87, IDH1wt-U87, and IDH1R132H-U87 cells were incubated in normoxia 20% (left) or
hypoxia 1% (right) and cells were counted after 1, 3, and 7 days.
radio-chemosensitivity would be of clinical benefit. In this
study, we characterized the impact of IDH1mutation on U87
glioma cell growth and radiosensitivity.
2. Methods and Materials
2.1. Cell Culture and Hypoxia Treatment. The human
glioblastoma cell line U87 MG (HTB14) was obtained from
the American Type Culture Collection (ATCC, Rockville,
MD) andmaintained in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin. Normoxic cells (21% O
2
)
were grown in a humidified-air atmosphere incubator
containing 95% air/5% CO
2
at 37∘C. Hypoxia experiments
were performed in a controlled atmosphere chamber





, and 5% CO
2
at 37∘C.
2.2. Production of Recombinant Expression Lentiviruses.
A recombinant pLenti7.3/V5-TOPO expression vector
(Invitrogen’s ViraPowerTM HiPerformTM Lentiviral
Expression Systems; catalog number K5320-00) containing
the human IDH1 wild type and IDH1R132H cDNA was
generated. The expression clones and the ViraPower
Packaging Mix were cotransfected into the 293FT Cell line
to produce lentiviral stocks, which were used to transduce
the mammalian U87 cell line. U87-IDH1wt and U87-IDH1R132
stable cell lines were acquired using EmGFP selection by flow
cytometry. The constructs was verified by DNA sequencing
and RT-qPCR analysis.
2.3. Cell Proliferation Assay in Normoxia and in Hypoxia. To
evaluate the impact of IDH1mutation on cell growth in nor-
moxia and in hypoxia by trypan blue dye exclusion method,
U87, U87-IDH1wt, andU87-IDH1R132H cells (4000/well) plated
in 24-well plates (6 plates in total) were incubated at 37∘C for
six hours in normoxia to adhere; then 3 plates were removed
at 37∘C in the controlled atmosphere chamber overnight. At
1, 3, and 7 days after exposure to normoxia and hypoxia,
the cells were trypsinized, and the number of viable cells
BioMed Research International 3
































Figure 3: Effect of IDH1R132H on U87 cell viability after irradiation. Transduced cells were plated and then irradiated with doses ranging from




































































Figure 4: Cell viability after 8Gy irradiation. Cells were counted
before 8Gy irradiation and 5 days after, in normoxia (20% O
2
) (left)
and in hypoxia (1% O
2
) (right).
per well was determined by counting with trypan blue. The
experiment was performed three times in triplicate each.
2.4. Comparative Cell Viability Assay after Irradiation, in
Normoxia and inHypoxia. To evaluate the effect of IDH1R132H
in the response to radiotherapy, U87 cells, IDH1wt-U87, and
IDH1R132H-U87 cells were plated (4.103 per well) in 24-well
plates. Six hours later at 37∘C in normoxia, plates were
either kept in normoxia or incubated in the controlled
atmosphere chamber 1% O
2
overnight. The next day, cells
were irradiated with doses ranging from 0 to 10Gy in
order to determine the most discriminating dose. Cells were
fixed in paraformaldehyde (PFA) 4%, then stained with
Hoechst 33342 (10 𝜇g/mL in PBS, Sigma-Aldrich, France) and
photographed in a blinded fashion under fluorescence (4
wells per condition; 4 photographs per well) at 24 h, 48 h, and
120 h, respectively. Cells were counted with ImageJ software
(Rasband, WS, ImageJ, US NIH).
2.5. Colony-Formation Assay in Normoxia and in Hypoxia.
U87, IDH1wt-U87, and IDH1R132H-U87 cells were plated in 6-
well containing 0.3% base agar layer. Six hours later, cells
were either incubated in the hypoxic or normoxic chamber
overnight.Thenext day, the cells were treated by radiotherapy
at the Radiotherapy Department of the Centre de Lutte
Contre le Cancer (CLCC) Franc¸ois Baclesse (Caen, France)
using an X-ray generator with doses ranging 0–8Gy (Therac
15-Saturne with a dose rate of 2Gy/min) and then incubated
again for colony formation. One month later, the colonies
were fixed in 20% ethanol and stained with 0.05% crystal
violet. Colonies that contained more than 50 cells were
counted. Survival was calculated as the average number
of colonies counted divided by the number of cells plated
multiplicated by plating efficiency (PE), where PE is the
fraction of colonies counted divided by cells plated without
radiation. The clonogenic survival data were generated using
JMP software. The experiment was performed five times in
triplicate each.
2.6. Statistical Analysis. Results obtained in vitro were
expressed asmean± SEM Image analysis was performedwith
in-house macros under the ImageJ Software (Rasband, WS,
ImageJ, US NIH). All statistical analyses were determined
using post hoc tests after significant ANOVA. Values of 𝑃 <
0.05 were considered statistically significant.
3. Results
3.1. Transduced Cells Express High Quantities of IDH1wt and
IDH1R132H. The presence of IDH1R132H transduced gene was
confirmed byDNA sequencing. Real time PCR showed a high
expression of gene IDH1wt and IDH1R132H in transduced U87
cells compared to nontransduced cells (Figure 1).
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Figure 5: IDH1R132H-U87 cells have a reduced colony forming cell ability after irradiation in hypoxia. U87, IDH1wt-U87, and IDH1R132H-U87
cells were plated 24 h before irradiation (0-2-4-6-8Gy) in agar and incubated for one month in normoxia (20% O
2
) and in hypoxia (1%
O
2
). The colonies were fixed in ethanol, stained with 0.05% crystal violet, and counted. Survival rate was estimated by the ratio between the
colonies count and the number of cells plated, multiplicated by the plating efficiency.
3.2. IDH1R132H Expressing U87 Glioma Cells Grow Faster
in Hypoxia. We determined whether IDH1R132H expression
directly influences cell growth in normoxia and in hypoxia.
The viable cell number per well was determined by counting
with trypan blue at 1, 3, and 7 days after incubation in
normoxia and in hypoxia. Proliferation rate ofU87-IDH1R132H
cells was significantly higher in normoxia than in hypoxia
for all the three cell lines. In normoxia, U87, U87-IDH1wt,
and U87-IDH1R132H cells grew at the same rate, whereas U87-
IDH1R132H grew faster than U87 and U87-IDH1wt in hypoxia
(Figure 2).
3.3. Effect of Transduced IDH1R132H on Cell Viability upon
Exposure to Doses Ranging 0 to 10 Gy in Normoxia and in
Hypoxia. To evaluate the role of IDH1R132H in the response
to radiotherapy, U87, U87-IDH1wt, and U87-IDH1R132H were
exposed to different doses (range: 0–10Gy): in normoxia
the three cell lines showed the same radiosensitivity profile,
whereas in hypoxia, the viability of U87-IDH1R132H cells was
significantly lower after 5 days compared to control cells and
IDH1wt cells (Figure 3) (13% versus 23% and 22% for a dose
of 10Gy, 𝑃 < 0.001), respectively. This result suggests that
IDH1R132H makes the cells more radiosensitive in hypoxic, but
not in normoxic conditions.
3.4. Effect of Transduced IDH1R132H onCellMortality over Time
following 8Gy Irradiation in Normoxia and in Hypoxia. We
quantified then cell death at 24 h, 48 h, and 120 h after 8Gy
irradiation.There was no substantial cell death after 24 h.The
effect appeared at 48 h in both normoxia and in hypoxia (data
not shown) and was maximal after 5 days. Cell death was
significantly higher for IDH1R132H transduced cells in hypoxia
but not in normoxia (Figure 4).
3.5. Radiosensitivity of U87- IDH1R132H in Hypoxia Is Con-
firmed by Colony-Formation Assay. A colony-formation
assay was used to confirm the effect of IDH1R132H on the
response to radiotherapy. Cells were treated with graded
doses of radiation (0, 2, 4, 6, and 8Gy). Colony-forming
efficiency was determined 1 month later and surviving
fractions were calculated. In normoxia, U87, U87-IDH1wt,
and U87-IDH1R132H had the same colony-formation capacity
after radiotherapy. In hypoxia, the colony number of U87-
IDH1R132H after radiotherapy was significantly lower than
U87 and U87-IDH1wt (Figure 5). Thus, U87-IDH1R132H signif-
icantly sensitized U87 glioma cells to radiation.
4. Discussion
We observed here that IDH1 mutated U87 grew faster in
moderate hypoxic conditions (1% O
2
) than in normoxia
(21% O
2
). This contrast with data obtained in normoxia,
IDH1R132H overexpression in established glioma cell lines in
vitro, resulted in a marked decrease in proliferation and mice
injected with IDH1R132H-U87 cells had prolonged survival
compared to mice injected with IDH1wt-U87 cells [12].
We found then that IDH1R132H-U87 were more sensitive
to radiotherapy in hypoxic condition. Indeed a high rate of
cell proliferation is per se a sensitive factor of the radiation
therapy response. But on the other hand, IDH1/IDH2mutated
cells may be more sensitive to oxidative stress. The role of
isocitrate dehydrogenase in cellular defense against oxidative
stress has been suggested [13]. Indeed, IDH1/IDH2 serves as
a major source of cytosolic and mitochondrial NADPH pro-
duction necessary to regenerate reduced glutathione (GSH)
by glutathione reductase and for the activity of NADPH-
dependent thioredoxin system, both are important in the
protection of cells from oxidative damage [14, 15]. Thus, the
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decrease ofNADPH in IDH1/IDH2mutated cellsmight result
in an increase of ROS that can damage DNA. Partially in
line with our results, U87 cells transduced with IDH1R132H or
IDH2R172K demonstrated increased sensitivity to radiation but
the effect observed in normoxia and hypoxic conditions was
not investigated [16].
Despite hypoxia being considered as a factor of radiore-
sistance, we observed here a radiosensitizing effect of
IDH1R132H in glioblastoma cell line in hypoxic but not in
normoxic condition. Until recently, IDH1/2 mutations were
believed to result in the stabilization of HIF1𝛼 [10, 17].
Interestingly Koivunen et al. [11] showed that D-2HG (but not
L-2HG) instead of being an inhibitor of EGLN (HIF prolyl 4-
hydroxylases) activity acts as a partial agonist of EGLN and
promotes the degradation of HIF1𝛼. Because HIF protects
cells from irradiation therapy under hypoxic condition,
we may hypothesize that IDH mutation, by inducing an
inappropriate degradation of HIF, could make the mutated
cell more vulnerable to RT.
In conclusion, this study suggests a radiosensitizing effect
of IDH1R132H in glioblastoma cell lines U87 grown under mild
hypoxic conditions, which are close to in vivo conditions. We
need to confirm this finding on clinical setting: the 1p19q
codeletion is a known marker of chemosensitivity. Whether
the IDH1/2mutation is a marker of radiosensitivity should be
determined.The ongoing EORTC trial on low grade gliomas,
which randomizes radiotherapy versus chemotherapy in low
grade gliomas at progression and includes also a prospective
observational cohort, will be pivotal to answer this question.
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